MichelleA.FanaleMD

Oncology • Bothell, WA

Hematologic Oncology

Executive Medical Director, Lymphoma Strategy

Join to view full profile

Dr. Fanale is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fanale's full profile

Already have an account?

Office
Seagen - Headquarters
21717 30th Drive S.E, Building 3
Bothell, WA 98021
Phone+1 425-527-4000

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Rutgers New Jersey Medical SchoolClass of 1999
Rutgers College BA, Biochemistry/ Molecular Biology & Psychology , 1990 - 1994

Certifications & Licensure

TX State Medical License 2002 - 2022
AZ State Medical License 2001 - 2017
MN State Medical License 2000 - 2015

Clinical Trials

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma Start of enrollment: 2006 Aug 01
Terminated
Phase 2
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma Start of enrollment: 2007 Feb 01
Completed
Phase 1
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2008 Mar 19
Completed
Phase 2
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. Start of enrollment: 2009 Aug 24
Completed
Phase 2
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2011 Jun 21
Completed
Phase 1
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Start of enrollment: 2011 Nov 01
Active, not recruiting
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Start of enrollment: 2013 Jul 17
Completed
Phase 1
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) Start of enrollment: 2014 Aug 12
Completed
Phase 2
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Start of enrollment: 2017 Mar 08
Recruiting
Phase 1, Phase 2
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Start of enrollment: 2017 Apr 24
Active, not recruiting
Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Start of enrollment: 2017 May 25
Active, not recruiting
Phase 2
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Start of enrollment: 2017 Jul 18
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
Darcy R Flora, Susan K Parsons, Nicholas Liu, Kristina S Yu, Katherine Holmes
British Journal of Haematology. 2024-04-01
1 citations
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, David J Straus, Kerry J Savage
Haematologica. 2024-03-01
3 citations
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma ...
Stefan K Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye
Clinical Lymphoma, Myeloma & Leukemia. 2024-02-01

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study
Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica

Lectures

Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

My B-cell Lymphoma Treatment During PregnancyJune 21st, 2018
Novel Agents Show Impressive Activity in Hodgkin LymphomaOctober 27th, 2017
Longer Nivolumab Response Reported in Hodgkin Lymphoma PatientsAugust 10th, 2017

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member